[5] Kong Y, Dong Q, Jin P, et al.Updated Efficacy and Safety of SOX regimen combined with inetetamab as first-line treatment for HER2-positive advanced gastric cancer. ESMO ASIA.2024.158P. [6] Janjigian, Y.Y., ...
13. Saura Manich C, O’Shaughnessy J, Aftimos PG, et al. LBA15 primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treat...
[12] Powles RL, Redmond D, Sotiriou C, et al. Association of T-cell receptor repertoire use with response to combined trastuzumab-lapatinib treatment of HER2-positive breast cancer: secondary analysis of the NeoALTTO randomized clinical trial. JAMA Oncol. 2018;4: e181564 [13] Dieci MV, Prat...
《2022 ASCO Educational Book》发表的一篇报道“Systemic Therapy for HER2-Positive Metastatic Breast Cancer:Moving Into a New Era”指出,当前HER2阳性转移性乳腺癌(MBC)的治疗目标是根据疾病和患者的特征量身定制治疗强度,以提高治愈率,同时将过度治疗风险降到最低,这为制定HER2阳性MBC的治疗策略提示了重要方向。
13. Saura Manich C, O’Shaughnessy J, Aftimos PG, et al. LBA15 primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Ann Oncol....
6.Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742...
[11] André F, Hee Park Y, Kim SB, et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 May 27;401(10390):1773-1785. ...
Harbeck N, Wrobel D, Zaiss M, et al. Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study. Breast Care. 2023. ...
Escriva-de-Romaní ´ SI, et al. Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Ann Oncol 2021;32(suppl 5):S1288. Abstr...
[9]Escrivá-de-RomaníS,ArumíM,Bellet M,et al.HER2-positive breast cancer:current and new therapeutic strategies.Breast.2018;39:80–88. [10]Whitehead I,IrwinG W,Bannon F,et al.The NeST(neoadjuvant systemic therapy in breast cancer)study:National Practice Questionnaire of United Kingdom multi...